US Regulatory Landscape not Improving for Ultra-Rare Disease Therapies
March 2, 2023
Axinn partner Chad Landmon was quoted in the BioWorld article, "US Regulatory Landscape not Improving for Ultra-Rare Disease Therapies."
Click here to access the article.